Naringenin improves insulin sensitivity in a gestational diabetes model. - GreenMedInfo Summary
Naringenin improves insulin sensitivity in gestational diabetes mellitus mice through AMPK.
Nutr Diabetes. 2019 Oct 7 ;9(1):28. Epub 2019 Oct 7. PMID: 31591391
Sen Li
BACKGROUND: Gestational diabetes mellitus (GDM) is a temporary form of diabetes during pregnancy, which influences the health of maternal-child in clinical practice. It is still urgent to develop new effective treatment for GDM. Naringenin is a bioactive ingredient with multiple activities including anti-diabetic. In current study, the effects of naringenin on GDM symptoms, insulin tolerance, inflammation, and productive outcomes were evaluated and the underlying mechanisms were explored.
METHODS: We administrated naringenin to GDM mice and monitored the GDM symptoms, glucose and insulin tolerance, inflammation and productive outcomes. We established tumor necrosis factor alpha (TNF-α)-induced insulin resistance skeletal muscle cell model and evaluated the effects of naringenin on reactive oxygen species (ROS) production, glucose uptake and glucose transporter type 4 (GLUT4) membrane translocation.
RESULTS: We found that naringenin ameliorated GDM symptoms, improved glucose and insulin tolerance, inhibited inflammation, and improved productive outcomes. It was further found that naringenin inhibited TNF-α-induced ROS production, enhanced GLUT4 membrane translocation, and glucose uptake, which were abolished by inhibition of AMP-activated protein kinase (AMPK).
CONCLUSION: Naringenin improves insulin sensitivity in gestational diabetes mellitus mice in an AMPK-dependent manner.
